CD38 and BCL2 expression guides treatment with daratumumab and venetoclax in tagraxofusp-refractory blastic plasmacytoid dendritic cell neoplasm (BPDCN) featuring dynamic loss of CD123

被引：2
|
作者：
Hu, Xiaoyi [1 ]
Ediriwickrema, Asiri [1 ]
Saleem, Atif [2 ]
Tan, Brent [1 ]
Pemmaraju, Naveen [3 ]
Mannis, Gabriel N. [1 ]
机构：
[1] Stanford Univ, Canc Inst, Dept Med, Div Hematol, Stanford, CA 94305 USA
[2] Stanford Univ, Sch Med, Dept Pathol, Stanford, CA USA
[3] Univ Texas MD Anderson Canc Ctr, Dept Leukemia, Houston, TX USA
来源：
LEUKEMIA RESEARCH | 2024年 / 139卷
关键词：
BPDCN; Tagraxofusp; CD123; Daratumumab; Venetoclax;
D O I：
10.1016/j.leukres.2024.107479
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页数：4
相关论文
共 22 条
  • [1] Relapse of tagraxofusp treated blastic plasmacytoid dendritic cell neoplasm with loss of CD123 expression
    Gulati, Rohit
    Abu-Salah, Asma
    Salous, Tareq
    Nassiri, Mehdi
    JOURNAL OF HEMATOPATHOLOGY, 2022, 15 (01) : 35 - 39
  • [2] Relapse of tagraxofusp treated blastic plasmacytoid dendritic cell neoplasm with loss of CD123 expression
    Rohit Gulati
    Asma Abu-Salah
    Tareq Salous
    Mehdi Nassiri
    Journal of Hematopathology, 2022, 15 : 35 - 39
  • [3] Treatment of Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) in Pediatric Patients with Tagraxofusp, a CD123-Targeted Therapy
    Pemmaraju, Naveen
    Cuglievan, Branko
    Lasky, Joseph L., III
    Kheradpour, Albert
    Hijiya, Nobuko
    Stein, Anthony S.
    Pawlowska, Anna B.
    BLOOD, 2021, 138
  • [4] Optimization of the CD123 CAR T-cell scFv for the treatment of patients with Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)
    Fredon, M.
    Poussard, M.
    Biichle, S.
    Anna, F.
    Bonnefoy, F.
    Bole-Richard, E.
    Renosi, F.
    Caumartin, J.
    Loustau, M.
    Adotevi, O.
    Saas, P.
    Angelot-Delettre, F.
    Galaine, J.
    Garnache-Ottou, F.
    HUMAN GENE THERAPY, 2021, 32 (19-20) : A37 - A37
  • [5] Novel Pathways and Potential Therapeutic Strategies for Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN): CD123 and Beyond
    Pemmaraju, Naveen
    CURRENT HEMATOLOGIC MALIGNANCY REPORTS, 2017, 12 (06) : 510 - 512
  • [6] Novel Pathways and Potential Therapeutic Strategies for Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN): CD123 and Beyond
    Naveen Pemmaraju
    Current Hematologic Malignancy Reports, 2017, 12 : 510 - 512
  • [7] Tagraxofusp, a CD123-Targeted Therapy, in Patients with Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN): Results of a Landmark Clinical Trial
    Pemmaraju, Naveen
    Lane, Andrew
    Sweet, Kendra
    Stein, Anthony
    Vasu, Sumithira
    Blum, William
    Rizzieri, David
    Wang, Eunice
    Duvic, Madeleine
    Brooks, Christopher
    Sloan, J. Mark
    Rosenblat, Todd
    Akilov, Oleg
    Mughal, Tariq
    Lancet, Jeffrey
    Kantarjian, Hagop
    Konopleva, Marina
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2020, 20 : S209 - S210
  • [8] TREATMENT OF BLASTIC PLASMACYTOID DENDRITIC CELL NEOPLASM IN PEDIATRIC PATIENTS WITH TAGRAXOFUSP, A CD123-TARGETED THERAPY
    Vinti, Luciana
    Pemmaraju, Naveen
    Pawlowska, Anna
    Cuglievan, Branko
    Lasky, Joseph
    Kheradpour, Albert
    Hijiya, Nobuko
    Stein, Anthony
    Meshinchi, Soheil
    Mullen, Craig
    Mughal, Tariq
    Angelucci, Emanuele
    PEDIATRIC BLOOD & CANCER, 2022, 69 : S195 - S196
  • [9] Treatment of Blastic Plasmacytoid Dendritic Cell Neoplasm in Pediatric Patients With Tagraxofusp, a CD123Targeted Therapy
    Pemmaraju, Naveen
    Cuglievan, Branko
    Lasky, Joseph
    Kheradpour, Albert
    Hijiya, Nobuko
    Stein, Anthony S.
    Meshinchi, Soheil
    Mullen, Craig
    Angelucci, Emanuele
    Vinti, Luciana
    Mughal, Tariq I.
    Pawlowska, Anna
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2022, 22 : S244 - S245
  • [10] Tagraxofusp, the first CD123-targeted therapy and first targeted treatment for blastic plasmacytoid dendritic cell neoplasm
    Economides, Minas P.
    McCue, Deborah
    Lane, Andrew A.
    Pemmaraju, Naveen
    EXPERT REVIEW OF CLINICAL PHARMACOLOGY, 2019, 12 (10) : 941 - 946
123